EFFECT OF RILUZOLE ON LEVELS OF BRAIN LACTATE IN PATIENT WITH HUNTINGTON'S DIS

利鲁唑对亨廷顿舞蹈症患者脑乳酸水平的影响

• 批准号: 6280034
• 负责人: Walter J. Koroshetz
• 金额: $ 2.74万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6280034
• 关键词: Huntington's disease; amyotrophic lateral sclerosis; brain metabolism; clinical research; clinical trial phase I; drug administration rate /duration; drug screening /evaluation; human subject; human therapy evaluation; lactates; magnetic resonance imaging; mental disorder chemotherapy; nervous system disorder chemotherapy; thiazide

This protocol is a pilot study that will investigate the use of riluzole in patients with Huntington's Disease (HD). Riluzole has shown promise in the treatment of amyotrophic lateral sclerosis, another neuro- degernative disorder. The investigators will administer riluzole to 8 subjects with HD for 6 weeks as an open-label study. The study endpoint will include changes in brain lactate levels as measured by MR spectroscopy following administration of the study drug and four weeks after stopping medication.

本方案是一项初步研究，将调查利鲁唑的使用 在患有亨廷顿病（HD）的患者中。阿舒唑显示出了希望 在肌萎缩侧索硬化症的治疗中，另一种神经- 退行性疾病研究者将给予利鲁唑至8 作为一项开放标签研究，在HD受试者中进行6周。研究终点 将包括通过MR测量的脑乳酸水平的变化 研究药物给药后和给药后4周 停止用药后。